Aurinia Pharmaceuticals (AUPH) Research Coverage Started at Royal Bank of Canada

Royal Bank of Canada assumed coverage on shares of Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) in a report released on Thursday, MarketBeat.com reports. The brokerage set an “outperform” rating and a $9.00 price target on the biotechnology company’s stock. Royal Bank of Canada’s price target points to a potential upside of 76.47% from the stock’s current price.

Several other equities research analysts have also recently weighed in on AUPH. Cantor Fitzgerald reaffirmed a “buy” rating and set a $14.00 price objective on shares of Aurinia Pharmaceuticals in a research report on Monday, October 23rd. Leerink Swann upped their price objective on shares of Aurinia Pharmaceuticals from $10.00 to $14.00 and gave the stock an “outperform” rating in a research report on Monday, October 23rd. Zacks Investment Research cut shares of Aurinia Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, October 24th. Canaccord Genuity set a $11.00 target price on shares of Aurinia Pharmaceuticals and gave the stock a “buy” rating in a report on Tuesday, October 24th. Finally, HC Wainwright reissued a “buy” rating and issued a $12.00 target price (up previously from $10.00) on shares of Aurinia Pharmaceuticals in a report on Monday, October 30th. Two research analysts have rated the stock with a sell rating, one has issued a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. Aurinia Pharmaceuticals currently has an average rating of “Buy” and a consensus target price of $10.59.

Aurinia Pharmaceuticals (NASDAQ:AUPH) traded up $0.04 on Thursday, reaching $5.10. 825,344 shares of the company traded hands, compared to its average volume of 1,054,128. Aurinia Pharmaceuticals has a 1-year low of $3.21 and a 1-year high of $10.54. The company has a market capitalization of $428.26, a PE ratio of -3.86 and a beta of 2.38.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last posted its quarterly earnings data on Tuesday, November 14th. The biotechnology company reported ($0.16) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.14) by ($0.02). Aurinia Pharmaceuticals had a negative return on equity of 25.56% and a negative net margin of 18,089.02%. The firm had revenue of $0.03 million for the quarter, compared to the consensus estimate of $0.03 million. The firm’s revenue for the quarter was up .0% compared to the same quarter last year. analysts expect that Aurinia Pharmaceuticals will post -1.08 EPS for the current fiscal year.

Several hedge funds have recently bought and sold shares of the company. BlackRock Inc. bought a new position in shares of Aurinia Pharmaceuticals in the fourth quarter worth about $3,261,000. Swiss National Bank bought a new position in shares of Aurinia Pharmaceuticals in the fourth quarter worth about $421,000. Cutler Capital Management LLC lifted its holdings in shares of Aurinia Pharmaceuticals by 25.0% in the fourth quarter. Cutler Capital Management LLC now owns 50,000 shares of the biotechnology company’s stock worth $226,000 after acquiring an additional 10,000 shares during the last quarter. Alyeska Investment Group L.P. lifted its holdings in shares of Aurinia Pharmaceuticals by 1.8% in the third quarter. Alyeska Investment Group L.P. now owns 681,517 shares of the biotechnology company’s stock worth $4,273,000 after acquiring an additional 12,171 shares during the last quarter. Finally, Investment Centers of America Inc. lifted its holdings in shares of Aurinia Pharmaceuticals by 100.0% in the third quarter. Investment Centers of America Inc. now owns 60,000 shares of the biotechnology company’s stock worth $376,000 after acquiring an additional 30,000 shares during the last quarter. 28.08% of the stock is owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION NOTICE: This article was originally posted by American Banking News and is the sole property of of American Banking News. If you are accessing this article on another site, it was illegally stolen and reposted in violation of United States & international trademark & copyright law. The legal version of this article can be viewed at https://www.americanbankingnews.com/2018/02/11/aurinia-pharmaceuticals-auph-research-coverage-started-at-royal-bank-of-canada.html.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company’s primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN.

Analyst Recommendations for Aurinia Pharmaceuticals (NASDAQ:AUPH)

Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply